Trump ends business groups as CEOs quit


FTSE-100
FTSE-100 Chart (1 Year)

FTSE-100 1 Year Chart

Today’s edition features:

  • Armadale Capital (ACP.L)
  • Bushveld Minerals (BMN.L)
  • Nu-Oil & Gas (NUOG.L)
  • Tiziana Life Sciences (TILS.L)

Visit Company News »


Markets

Europe
The FTSE-100 finished yesterday’s session 0.67% higher at 7,433.03 whilst the FTSE AIM All-Share index was up 0.08% at 1,003.01. In continental Europe, the CAC-40 finished 0.71% higher at 5,176.61 whilst the DAX was up 0.71% at 12,263.86.

Wall Street
In New York last night, the Dow Jones ended 0.12% higher at 22,024.87, the S&P 500 rose 0.14% to 2,468.11 and the Nasdaq climbed 0.19% at 6,345.11.

Asia
In Asian markets this morning, the Nikkei 225 and the Hang Seng were both flat midway through an up-and-down session at 19,728.48 and 27,408.66, respectively.

Oil
In early trade today, WTI crude was up 0.28% at $46.19 per barrel and Brent crude was 0.5% higher at $50.52 per barrel.


Headlines

Trump ends business groups as CEOs quit
President Trump has said he is scrapping two business councils after more bosses quit over his handling of violent clashes in Virginia. Business leaders left the White House manufacturing council after the backlash against how he reacted to the far-right rally last weekend. The clashes culminated in a woman’s death and nearly 20 wounded when a car ploughed into a crowd of anti-fascists. Mr Trump’s reaction has sparked outrage and generated global headlines. His announcement on Twitter came as the heads of 3M, Campbell Soup, Johnson & Johnson and United Technologies announced their resignations on Wednesday. Mr Trump said: “Rather than putting pressure on the businesspeople of the Manufacturing Council & Strategy & Policy Forum, I am ending both.” Before Mr Trump’s announcement, the Strategy and Policy Forum announced it was a joint decision to disband the council. Businesses have been under pressure to distance themselves from Mr Trump over his handling of the clashes in Charlottesville, Virginia.

Source: BBC News



Company news

Armadale Capital (ACP.L, 1.28p) – Speculative Buy
Armadale has completed its first phase of this year’s drilling at its flagship graphite project in Tanzania, Mahenge Liandu. The drilling targeted near surface mineralisation and successfully defined a 1.2km strike length with good widths. Metallurgical test work of a bulk sample is also underway and initial results show good recoveries – 98% at the rougher stage. A second stage of RC drilling will look to increase the strike to 2.4km, both phase 1 and 2 should add considerably to the maiden resource of 41Mt grading 9.4% total graphite carbon.

Our View: This is a a very positive news release. Armadale is moving quickly, adding tonnes and focusing on metallurgical work concurrently. This project looks to have substantial scale and initial work on the metallurgy of the ore is encouraging. Note that the Tanzania graphite in this area has very low levels of deleterious elements, something that some Mozambican projects struggle with. We have a Speculative Buy recommendation.

Beaufort Securities acts as a corporate broker to Armadale Capital plc

REQUEST A CALL FROM A BROKER REGARDING THIS RECOMMENDATION

Bushveld Minerals (BMN.L, 9.50p) – Speculative Buy
Bushveld Energy (subsidiary of Bushveld Minerals) published an update on its vanadium redox flow battery business. Working with the Industrial Development Corporation, in 2H16 Bushveld commissioned market studies to estimate African VRFB demand and global vanadium electrolyte demand. The study showed that African VRFB demand will mostly be for off-grid power applications, while global vanadium electrolyte demand will increase to 40-60 megalitres of vanadium electrolyte per annum. Bushveld and IDC are also progressing a “techno economic study” of a vanadium electrolyte production plant in South Africa. This is particularly interesting since 70% of the manufacturing cost of electrolytes is the vanadium feedstock where, through Vametco, Bushveld has a source of long term low cost supply. The capital cost of a vanadium electrolyte plant is circa $10m so well within Bushveld’s funding capabilities. The next stage is a more detailed study of a vanadium electrolyte production plant to determine production costs, site locations (in SA) and technical studies on the quality of an electrolyte produced from Vametco.

Our View: The vanadium electrolyte market is a fast growing an exciting space which provides the longer lasting battery storage that lithium batteries do not. Bushveld is extremely well placed to build a vanadium electrolyte business, especially since it has access to vanadium supplies and the capex of a plant is relatively modest. We have a Speculative Buy recommendation.

Beaufort Securities acts as a corporate broker to Bushveld Minerals plc

REQUEST A CALL FROM A BROKER REGARDING THIS RECOMMENDATION

Nu-Oil & Gas (NUOG.L, 1.12p) – Speculative Buy
NU-Oil & Gas has received confirmation that its Western Newfoundland petroleum lease PL2002-01(A) has been renewed for 5 years. NU-Oil’s partner PVF is providing 100% of the finance to try and restore production on the PAP#1-ST#3 well. Once PVF has recouped its costs, net revenue will be shared 50:50 between PVF and NU-Oil. PVF’s work programme involves a workover and insertion of an artificial lift system. PVF may also look to drill additional wells, although this would be under a new agreement. We expect newsflow regarding the PVF worker in the coming weeks.

Our View: NU-Oil remains committed to its strategy of building a marginal field development business. However, its project in Newfoundland should provide positive news and has the potential to generate significant cashflows for NU-Oil. Obviously this will depend on the success of PVF’s worker and recompletion programme. We have a Speculative Buy recommendation.

Beaufort Securities acts as a corporate broker to Nu-Oil & Gas plc

REQUEST A CALL FROM A BROKER REGARDING THIS RECOMMENDATION

Tiziana Life Sciences (TILS.L, 160.12p) – Speculative Buy
Tiziana, the clinical stage biotechnology company developing targeted drugs for cancer and autoimmune diseases, yesterday announced that with respect to the to the proposals announced on 12 July 2017, the holders of the Company’s Convertible Loan Note (‘CLN’) and Warrant have agreed to convert all of the loan notes and vary the terms of the warrants substantially prior to the intended deadline. The proposal was that CLN Holders be offered an additional bonus coupon of three years of interest at the relevant applicable rate of return for agreeing to the immediate conversion of the CLNs into ordinary shares. The CLN Holders have now agreed to the proposal and the Company therefore has issued 27,645,013 new ordinary shares to the CLN Holders (represent 22.3% of the enlarged share capital of the Company). All of the new shares are subject to a restriction on disposal for a period of 12 months. Further to this, the Company also proposed to vary the terms of the warrants associated with the CLNs by extending the exercise period of these warrants to 31 December 2021. The Warrant Holders have agreed the proposal, including acceptance of the condition that the ordinary shares they receive upon conversion of the warrants will also be subject to a restriction not to dispose of the relevant underlying shares for a period of 12 months following exercise of the warrants. Outstanding warrants to subscribe for totaled 4,239,579 ordinary shares at exercise prices between 50p and £2.50. Beside this, the Company has granted options over a total of 10,149,403 ordinary shares of which 4,752,500 are vested at exercise prices between 15p and £1.25p per share and 5,396,903 remain subject to vesting conditions (at potential exercise prices ranging from 15p to £1.925 per share). Altogether, the total number of Ordinary Shares in issue (including CLN conversion) will be 123,827,938, whilst fully diluted issued share capital of the Company assuming all options and warrants, vested and unvested, exercised and exercisable, were converted is 138,216,920 ordinary shares. Tiziana’s Chairman, Gabriele Cerrone, commented “Now that we have moved into Phase II clinical trials we have been focusing on increasing our exposure to both institutional investors and other international trading markets”.

Our View: The market reacted positively to yesterday’s announcement. The full conversion of CLNs into 27,645,013 new ordinary shares means the Company is now debt free and that its simplified capital structure enables it to improve both the trading liquidity and visibility. Successful conversion along with the 12 months disposal restriction on the new equity demonstrates continuing support and confidence from the CLN holders with respect to Tiziana’s pipeline and business plan. Tiziana continues to make encouraging operational progress. Last month, for example, the Company enrolled first patient for its phase IIa clinical trial of milciclib, a novel inhibitor of cyclin-dependent kinases (CDKs), in patients with refractory hepatocellular carcinoma (‘HCC’). HCC is the 5th most common cancer worldwide and the 2nd most common cause of death from cancer worldwide affecting both men and women (S. Mittal & H. El-Serag, 2013). The top line data is expected to be announced during Q4 2018. Tiziana is now also preparing clinical trials to show the efficacy of foralumab, a fully human anti-CD3 monoclonal antibody, in patients with Non-alcoholic steatohepatitis (‘NASH’) and type 2 diabetes. The recent publication of a research article in a prestigious journal, Clinical Immunology, highlighted the potential of oral therapy with foralumab for inflammatory diseases including NASH. Tiziana’s foralumab is the only fully human engineered anti-CD3 monoclonal antibody (mAb) in clinical development to date. Beyond this Tiziana has an exciting pipeline of products and opportunities; for prudence, however, Beaufort has modelled its valuation of Tiziana based just on milciclib and foralumab, applying a relatively aggressive 15% discount to its long-run cashflow model. This creates a valuation more than twice the current level based on anticipated milestone fees & royalties. Beaufort reiterates its Speculative Buy rating on the shares together with a price target of 400p/share.

Beaufort Securities acts as a corporate broker to Tiziana Life Sciences plc

REQUEST A CALL FROM A BROKER REGARDING THIS RECOMMENDATION

To read Beaufort’s full research archive click here

Compiled by:
Barry Gibb, Kazunaga Senga, Sheldon Modeland, Charles Long & Ben Maitland
(t) +44 (0) 207 382 8384
(e) info@beaufortsecurities.com


Weekly diary


Click here to see all this week’s planned corporate and economic announcements.


Recommendations
During the three months to end-July 2017, the number of stocks on which Beaufort Securities published recommendations was 205, and the recommendations were as follows: Buy – 75; Speculative Buy – 107; Hold – 19; Sell – 1.

Full definitions of the recommendations used by Beaufort Securities in its publications and their respective meanings can be found on our website here.

Important Risk Warnings and Disclaimers
This report is published by Beaufort Securities Ltd (“Beaufort Securities”). Beaufort Securities Ltd is Authorised and Regulated by the Financial Conduct Authority and is a Member of the London Stock Exchange.

RELIANCE ON THIS NOTE FOR THE PURPOSE OF ENGAGING IN ANY INVESTMENT ACTIVITY MAY EXPOSE YOU TO A SIGNIFICANT RISK OF LOSING ALL OF THE FUNDS, PROPERTY OR OTHER ASSETS INVESTED OR OF INCURRING ADDITIONAL LIABILITY.

This document is not an offer to buy or sell any security or currency. This document does not provide you with individually tailored investment advice. It has been prepared without regard to the your financial circumstances and objectives The appropriateness of a particular investment or currency will depend on your individual circumstances and objectives. The investments and shares referred to in this document may not be suitable for you.

This research is non-independent and is classified as a Marketing Communication under FCA rules. As such it has not been prepared in accordance with legal requirements designed to promote independence of investment research and it is not subject to the prohibition on dealing ahead of the dissemination of investment research in COBS 12.2.5. However Beaufort Securities has adopted internal procedures which prohibit analysts from dealing ahead of non-independent research, except for legitimate market making and fulfilling clients’ unsolicited orders.

By receiving this document, you will not be deemed a client or provided with the protections afforded to clients of Beaufort Securities. When distributing this document, Beaufort Securities is not acting for you and will not be responsible for providing advice to you in relation to this document. Accordingly, Beaufort Securities will not be responsible to you for providing the protections afforded to its clients.

Beaufort Securities may effect transactions in shares mentioned herein and may take proprietary trading positions in those shares, and may receive remuneration for the publication of its research and for other services. Beaufort Securities may be a shareholder in any of the companies mentioned in this report. Accordingly, this document may not be considered as objective or impartial. Additionally, information may be available to Beaufort Securities or the Group, which is not reflected in this material. The remuneration of the author of this report is not tied to the recommendations on any shares mentioned nor to the any transactions undertaken by Beaufort Securities or any affiliate company. Further information on Beaufort Securities’ policy regarding potential conflicts of interest in the context of investment research and Beaufort Securities’ policy on disclosure and conflicts in general are available on request. Please refer to http://www.beaufortsecurities.com/important-info.

Past performance is not a guarantee of future performance. Investments may go down in value as well as up and you may not get back the full amount invested. The listing requirements for securities listed on AIM or NEX are less demanding and trading in them may be less liquid than main markets. This may make it more difficult to buy and sell these securities.

This document includes certain statements, estimates, and projections with respect to the anticipated future performance of securities listed on stock exchanges and as to the market for these shares. Such statements, estimates, and projections are based on information that we consider reliable and may reflect various assumptions made concerning anticipated economic developments, which have not been independently verified and may or may not prove correct. No representation or warranty is made as to the accuracy of such statements, estimates, and projections or as to its fitness for the purpose intended and it should not be relied upon as such. Opinions expressed are our current opinions as of the date appearing on this material only and may change without notice. Other third parties may have issued other reports that are inconsistent with, and reach different conclusions from, the information presented in this report. Those reports reflect the different assumptions, views, and analytical methods of the analysts who prepared them. This report has not been disclosed to any of the companies mentioned herein prior to its publication.

This document is based on information Beaufort Securities has received from publicly available reports and industry sources. Beaufort Securities may not have verified all of this information with third parties. Neither Beaufort Securities nor its advisors, directors or employees can guarantee the accuracy, reasonableness or completeness of the information received from any sources consulted for this publication, and neither Beaufort Securities nor its advisors, directors or employees accepts any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection with this document (except in respect of wilful default and to the extent that any such liability cannot be excluded by the applicable law). You should not rely on this document and should not use it substitution for the exercise of the independent judgment of yourself or your adviser.

The information contained in this document is confidential and is solely for use of those persons to whom it is addressed and may not be reproduced, further distributed to any other person or published, in whole or in part, for any purpose. Other persons who receive this document should not rely on it. Beaufort Securities, its directors, officers and employees may have positions in the securities mentioned herein.


Beaufort Securities Limited, 63 St Mary Axe, London, EC3A 8AA.
Authorised and regulated by the Financial Conduct Authority (Register No. 155104).
Members of the London Stock Exchange, NEX and QCA.

Be Sociable, Share!

Comments are closed.